Jasper Therapeutics(JSPR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

JSPR Jasper Therapeutics

Not Yet Opened 02-18 16:00:00 EST

1.34

+0.13

+10.74%

盘后1.40

+0.06+4.48%

19:43 EST

High1.40	Low1.20	Vol759.90K
Open1.27	D1 Closing1.21	Amplitude16.12%
Mkt Cap37.50M	Tradable Cap30.57M	Total Shares27.98M
T/O990.19K	T/O Rate3.33%	Tradable Shares22.81M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"JSPR","market":"US","secType":"STK","nameCN":"Jasper Therapeutics","latestPrice":1.34,"timestamp":1771448400000,"preClose":1.21,"halted":0,"volume":759898,"hourTrading":{"tag":"盘后","latestPrice":1.4,"preClose":1.34,"latestTime":"19:43 EST","volume":2394,"amount":3384.7926,"timestamp":1771461784585,"change":0.06,"changeRate":0.044776,"amplitude":0.060373},"delay":0,"changeRate":0.10743801652892572,"floatShares":22810300,"shares":27984039,"eps":-5.78681,"marketStatus":"Not Yet Opened","change":0.13,"latestTime":"02-18 16:00:00 EST","open":1.27,"high":1.395,"low":1.2,"amount":990185.3928592,"amplitude":0.161157,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-5.78681,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1771491600000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":1.21,"postHourTrading":{"tag":"盘后","latestPrice":1.4,"preClose":1.34,"latestTime":"19:43 EST","volume":2394,"amount":3384.7926,"timestamp":1771461784585,"change":0.06,"changeRate":0.044776,"amplitude":0.060373},"volumeRatio":1.072713,"impliedVol":0.6832,"impliedVolPercentile":0.1912},"requestUrl":"/m/hq/s/JSPR","defaultTab":"news","newsList":[{"id":"2603305996","title":"Jasper Therapeutics initiated with a Buy at Rodman & Renshaw","url":"https://stock-news.laohu8.com/highlight/detail?id=2603305996","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603305996?lang=en_us&edition=fundamental","pubTime":"2026-01-14 04:20","pubTimestamp":1768335615,"startTime":"0","endTime":"0","summary":"Rodman & Renshaw analyst Mike King initiated coverage of Jasper Therapeutics (JSPR) with a Buy rating and $17 price target Published first on TheFl...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/jasper-therapeutics-initiated-with-a-buy-at-rodman-renshaw-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/jasper-therapeutics-initiated-with-a-buy-at-rodman-renshaw-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","JSPR"],"gpt_icon":0},{"id":"2603542792","title":"Jasper Therapeutics Showcases Briquilimab’s Potential in Targeted Mast Cell Depletion for Inflammatory Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2603542792","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603542792?lang=en_us&edition=fundamental","pubTime":"2026-01-13 01:02","pubTimestamp":1768237364,"startTime":"0","endTime":"0","summary":"Jasper Therapeutics Inc. provided an update on its lead investigational drug, briquilimab, highlighting its targeted mast cell depletion capabilities in multiple inflammatory diseases, including chronic urticaria and asthma. The presentation details briquilimab’s mechanism of action, which involves direct, high-affinity blockade of the KIT receptor, leading to rapid and durable clinical responses. Clinical data from over 95 patients across multiple studies, including BEACON, SPOTLIGHT, and OLE, demonstrated significant reductions in disease activity scores and a favorable safety profile, with most adverse events being mild and transient. The results support the initiation of a Phase 2b study in chronic spontaneous urticaria, planned to enroll 75-100 patients to further evaluate two dosing regimens against placebo. Briquilimab remains an investigational drug and is not approved for any indication. You can access the full presentation through the link below.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL96YnJH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JSPR","BK4139"],"gpt_icon":0},{"id":"2602512394","title":"Briquilimab’s Robust Efficacy and Favorable Safety in Urticaria Indicate Strong Upside for Jasper Therapeutics and Support a Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2602512394","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602512394?lang=en_us&edition=fundamental","pubTime":"2026-01-09 01:55","pubTimestamp":1767894936,"startTime":"0","endTime":"0","summary":"Analyst Emily Bodnar from H.C. Wainwright maintained a Buy rating on Jasper Therapeutics and keeping the price target at $20.00. Emily Bodnar’s rat...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/briquilimabs-robust-efficacy-and-favorable-safety-in-urticaria-indicate-strong-upside-for-jasper-therapeutics-and-support-a-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/briquilimabs-robust-efficacy-and-favorable-safety-in-urticaria-indicate-strong-upside-for-jasper-therapeutics-and-support-a-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["JSPR"],"gpt_icon":0},{"id":"2601366198","title":"Jasper Therapeutics Reports Positive Updated Data From Briquilimab Studies in Chronic Spontaneous Urticaria","url":"https://stock-news.laohu8.com/highlight/detail?id=2601366198","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601366198?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:00","pubTimestamp":1767873650,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nFWN3Y81P2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","JSPR"],"gpt_icon":0},{"id":"2601366414","title":"Jasper Therapeutics Reports Positive Briquilimab Data in Chronic Spontaneous Urticaria Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2601366414","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601366414?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:00","pubTimestamp":1767873615,"startTime":"0","endTime":"0","summary":"Jasper Therapeutics Inc. announced positive updated clinical data from its BEACON Phase 1b/2a study and open label extension study evaluating briquilimab, a novel antibody therapy targeting KIT , in patients with chronic spontaneous urticaria  and chronic inducible urticaria . In the BEACON study, 83% of participants in the 240mg/180mg Q8W cohort achieved a complete response by week 3 after the initial dose, and 67% achieved a complete response at 12 weeks. In the open label extension study, 58% of CSU participants achieved a complete response at 12 weeks, and 75% achieved complete response or well controlled disease. KIT-related adverse events were low in frequency and predominantly low-grade. Jasper Therapeutics stated that these results provide sufficient data to inform dose selection for a planned Phase 2b study in CSU expected to begin in the second half of 2026. The company presented these results in a conference call and webinar, with presentation slides and webcast available on","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL75m7Lh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","SG9999014013.SGD","LU2095319765.USD","BK4139","JSPR","LU2210150020.SGD","SG9999014039.USD","BK4112","IE00B64PRP62.GBP","IE00BGHQF748.EUR","NDAQ","SG9999014005.SGD","BK4588","LU2210149790.SGD","LU0314104364.USD","BK4585","SG9999014021.USD","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2601038498","title":"BRIEF-Jasper Therapeutics Appoints Jeet Mahal As Chief Executive Officer To Lead Next Phase Of Clinical Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2601038498","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601038498?lang=en_us&edition=fundamental","pubTime":"2026-01-08 06:19","pubTimestamp":1767824363,"startTime":"0","endTime":"0","summary":"BRIEF-Jasper Therapeutics Appoints Jeet Mahal As Chief Executive Officer To Lead Next Phase Of Clinical GrowthJan 8 (Reuters) - Jasper Therapeutics Inc JSPR.O:JASPER THERAPEUTICS APPOINTS JEET MAHAL A","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nTUAJ5FFW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","JSPR"],"gpt_icon":0},{"id":"2601389746","title":"Jasper Therapeutics Names Jeet Mahal CEO and Thomas Wiggans Executive Chairperson","url":"https://stock-news.laohu8.com/highlight/detail?id=2601389746","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601389746?lang=en_us&edition=fundamental","pubTime":"2026-01-08 05:30","pubTimestamp":1767821409,"startTime":"0","endTime":"0","summary":"Jasper Therapeutics Inc. has appointed Jeet Mahal as President and Chief Executive Officer, effective January 5, 2026. Thomas Wiggans, previously Chairperson of the Board, has been named Executive Chairperson. Jeet Mahal also joins the company's Board of Directors. Ronald Martell is stepping down as CEO.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jasper Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on January 07, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDL8gJ0vq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","JSPR","NDAQ","SG9999014005.SGD","BK4588","SG9999014013.SGD","SG9999014039.USD","IE00BKPKM429.USD","BK4585","LU2095319765.USD","IE00B3QW5Z07.USD","BK4139","LU2210149790.SGD","LU0314104364.USD","BK4112","SG9999014021.USD","IE00BGHQF748.EUR","LU2210150020.SGD"],"gpt_icon":0},{"id":"2601897203","title":"Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2601897203","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601897203?lang=en_us&edition=fundamental","pubTime":"2026-01-08 05:30","pubTimestamp":1767821401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nTUAJ5FFW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","JSPR"],"gpt_icon":0},{"id":"2601897033","title":"Jasper Therapeutics Inc - Thomas Wiggans Appointed as Executive Chairperson of Jasper","url":"https://stock-news.laohu8.com/highlight/detail?id=2601897033","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601897033?lang=en_us&edition=fundamental","pubTime":"2026-01-08 05:30","pubTimestamp":1767821401,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nTUAJ5FFW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","JSPR"],"gpt_icon":0},{"id":"2588307230","title":"BUZZ-Jasper Therapeutics jumps as asthma drug shows early promise","url":"https://stock-news.laohu8.com/highlight/detail?id=2588307230","media":"Reuters","labels":["shareholding","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588307230?lang=en_us&edition=fundamental","pubTime":"2025-12-02 20:17","pubTimestamp":1764677875,"startTime":"0","endTime":"0","summary":"BUZZ-Jasper Therapeutics jumps as asthma drug shows early promise** Shares of drug developer Jasper Therapeutics JSPR.O  rise 17% to $2.02 in premarket trading** Co says early-stage study of its experimental drug briquilimab improved lung function and reduced airway inflammation in allergic asthma patients** Early-stage study enrolled about 17 patients in Canada; drug was well-tolerated with no serious safety issues - JSPR** Co's briquilimab targets mast cells, which trigger asthma symptoms and allergic reactions - JSPR** Up to last close, stock down ~92% YTD  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nL4N3X80TF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JSPR","BK4139"],"gpt_icon":0},{"id":"2588403082","title":"Jasper Therapeutics Inc: Briquilimab Was Well Tolerated in Study, Demonstrating a Favorable Safety Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2588403082","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588403082?lang=en_us&edition=fundamental","pubTime":"2025-12-02 20:00","pubTimestamp":1764676803,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nTUA1CK5N2:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["JSPR","BK4139"],"gpt_icon":0},{"id":"2588030846","title":"Jasper Therapeutics Reports Positive Preliminary Data From Etesian Study of Briquilimab in Asthma and Findings From Beacon Study Internal Investigation","url":"https://stock-news.laohu8.com/highlight/detail?id=2588030846","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588030846?lang=en_us&edition=fundamental","pubTime":"2025-12-02 20:00","pubTimestamp":1764676803,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nTUA1CK5N2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["JSPR","BK4139"],"gpt_icon":0},{"id":"2588030845","title":"Jasper Therapeutics Inc: Completion of Internal Beacon Study Investigation Noting No Deviations or Issues With Drug Product Utilized","url":"https://stock-news.laohu8.com/highlight/detail?id=2588030845","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588030845?lang=en_us&edition=fundamental","pubTime":"2025-12-02 20:00","pubTimestamp":1764676803,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nTUA1CK5N2:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","JSPR"],"gpt_icon":0},{"id":"2588037024","title":"NASDAQ TRADE HALT  HALT NEWS PENDING AT 06:55 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2588037024","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588037024?lang=en_us&edition=fundamental","pubTime":"2025-12-02 19:55","pubTimestamp":1764676500,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  HALT NEWS PENDING AT 06:55 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nAQN2LBO23:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JSPR","BK4139"],"gpt_icon":0},{"id":"2588031127","title":"Jasper Therapeutics to Present Preliminary Asthma and Urticaria Study Data in Investor Webinar","url":"https://stock-news.laohu8.com/highlight/detail?id=2588031127","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588031127?lang=en_us&edition=fundamental","pubTime":"2025-12-02 05:30","pubTimestamp":1764624611,"startTime":"0","endTime":"0","summary":"Jasper Therapeutics Inc. will host an investor webinar on Tuesday, December 2, 2025, at 8:00 am ET to present preliminary data from the ETESIAN study in asthma and findings from the BEACON study investigation. The event will feature remarks from Jasper management and Dr. Martin Metz, M.D., Professor of Dermatology and Allergy at Charité - Universittsmedizin Berlin and lead EU investigator in the BEACON study. A live question and answer session will follow the presentation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jasper Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on December 01, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL1hLC3T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","LU2095319765.USD","BK4139","JSPR","LU2210150020.SGD","BK4112","IE00B64PRP62.GBP","IE00BGHQF748.EUR","NDAQ","BK4588","LU2210149790.SGD","LU0314104364.USD","BK4585","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2582398645","title":"Jasper Therapeutics Is Maintained at Sector Perform by RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2582398645","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582398645?lang=en_us&edition=fundamental","pubTime":"2025-11-11 23:34","pubTimestamp":1762875240,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/JSPR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 11, 2025 10:34 ET (15:34 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0128525929.USD","LU0310800379.SGD","LU0708994859.HKD","BK4207","LU0029864427.USD","JSPR","LU1267930573.SGD","BK4139"],"gpt_icon":0},{"id":"2582360112","title":"Jasper Therapeutics Showcases Briquilimab’s Strong Efficacy and Safety in Chronic Urticaria","url":"https://stock-news.laohu8.com/highlight/detail?id=2582360112","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582360112?lang=en_us&edition=fundamental","pubTime":"2025-11-11 23:08","pubTimestamp":1762873736,"startTime":"0","endTime":"0","summary":"Jasper Therapeutics Inc. has provided an update on the development of briquilimab, its investigational drug for chronic urticaria, including chronic spontaneous urticaria  and chronic inducible urticaria . The company reported rapid, deep, and durable responses in clinical studies, with significant reductions in disease activity and high complete response rates observed in multiple patient cohorts. Briquilimab demonstrated a favorable safety profile, with most observed adverse events being low grade and not resulting in treatment discontinuation. Jasper is conducting further investigations into anomalous results in certain study cohorts, focusing on factors such as site operations and patient selection. Additional patient data and results from open-label extension studies are expected in the coming months. The company maintains global rights to develop and commercialize briquilimab across all indications. You can access the full presentation through the link below.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251111:nNDL7TNDJK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","JSPR"],"gpt_icon":0},{"id":"2582536224","title":"CoreWeave Bulls Should Brace For 'Wild, Lumpy, Volatile Ride,' JPMorgan Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2582536224","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582536224?lang=en_us&edition=fundamental","pubTime":"2025-11-11 22:03","pubTimestamp":1762869780,"startTime":"0","endTime":"0","summary":"JPMorgan downgrades CoreWeave, citing turbulence in AI infrastructure market. Despite near-term challenges, long-term growth...","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/11/CoreWeave-Inc-.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/11/CoreWeave-Inc-.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/tech/25/11/48778250/coreweave-bulls-should-brace-for-wild-lumpy-volatile-ride-jpmorgan-says","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/tech/25/11/48778250/coreweave-bulls-should-brace-for-wild-lumpy-volatile-ride-jpmorgan-says","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["IE00BJTD4N35.SGD","LU0345769128.USD","USJW.SI","LU0345770308.USD","LU1951198990.SGD",".IXIC","LU2286300806.USD","LU2552382132.HKD","LU2381873111.SGD","LU0820562030.AUD","BK4566","QID","BK4504","LU0211326755.USD","LU1668664300.SGD","NVIW.SI","SQQQ","MNQmain","IE00B19Z9Z06.USD","AI","USAW.SI","LU0345769631.USD","IE00BWXC8680.SGD","LU0208291251.USD","CRWV","NQmain","LU1244550577.SGD","IE00BKVL7J92.USD","RKUNY","LU0943347566.SGD","LU1992135399.USD","BK4528","LU1551013342.USD","JSPR","CRWD","TSYW.SI","LU0234572021.USD","TQQQ","LU0211326839.USD","LU1923623000.USD","LU1951200564.SGD","JPM","LU2552382058.USD","PSQ","QLD","LU0006306889.USD","IE000M9KFDE8.USD","LU0345770993.USD","BK4116"],"gpt_icon":1},{"id":"2582365353","title":"RBC Cuts Price Target on Jasper Therapeutics to $4 From $5, Keeps Sector Perform, Speculative Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2582365353","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582365353?lang=en_us&edition=fundamental","pubTime":"2025-11-11 19:51","pubTimestamp":1762861893,"startTime":"0","endTime":"0","summary":"Jasper Therapeutics (JSPR) has an average rating of overweight and mean price target of $12.67, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fro","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["JSPR"],"gpt_icon":0},{"id":"2582334454","title":"Jasper Therapeutics (JSPR) Receives a Hold from William Blair","url":"https://stock-news.laohu8.com/highlight/detail?id=2582334454","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582334454?lang=en_us&edition=fundamental","pubTime":"2025-11-11 13:35","pubTimestamp":1762839315,"startTime":"0","endTime":"0","summary":"William Blair analyst Matt Phipps maintained a Hold rating on Jasper Therapeutics yesterday. The company’s shares closed yesterday at $1.78. Phipps...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jasper-therapeutics-jspr-receives-a-hold-from-william-blair-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jasper-therapeutics-jspr-receives-a-hold-from-william-blair-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","JSPR"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.jaspertherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0806},{"period":"1month","weight":-0.1242},{"period":"3month","weight":-0.2386},{"period":"6month","weight":-0.5427},{"period":"1year","weight":-0.7763},{"period":"ytd","weight":-0.2678}],"compareEarnings":[{"period":"1week","weight":-0.0082},{"period":"1month","weight":-0.0078},{"period":"3month","weight":0.0517},{"period":"6month","weight":0.0635},{"period":"1year","weight":0.1223},{"period":"ytd","weight":0.0064}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is headquartered in Redwood City, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.285776},{"month":2,"riseRate":0.428571,"avgChangeRate":0.090051},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.012922},{"month":4,"riseRate":0.5,"avgChangeRate":-0.048363},{"month":5,"riseRate":0.833333,"avgChangeRate":0.048413},{"month":6,"riseRate":0.5,"avgChangeRate":-0.094073},{"month":7,"riseRate":0.166667,"avgChangeRate":-0.099771},{"month":8,"riseRate":0.5,"avgChangeRate":-0.007485},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.2127},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.027786},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.069737},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.008174}],"exchange":"NASDAQ","name":"Jasper Therapeutics","nameEN":"Jasper Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Jasper Therapeutics(JSPR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Jasper Therapeutics(JSPR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Jasper Therapeutics,JSPR,Jasper Therapeutics股票,Jasper Therapeutics股票老虎,Jasper Therapeutics股票老虎国际,Jasper Therapeutics行情,Jasper Therapeutics股票行情,Jasper Therapeutics股价,Jasper Therapeutics股市,Jasper Therapeutics股票价格,Jasper Therapeutics股票交易,Jasper Therapeutics股票购买,Jasper Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Jasper Therapeutics(JSPR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Jasper Therapeutics(JSPR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}